Satsuma Pharmaceuticals Inc (STSA) is trading 13% higher at $7.86 today. So far the Health Care sector has been having a somewhat gloomy day, and the share price of the company is outrunning it's peers.
1. STS101 has demonstrated a favorable safety and tolerability profile, consistent with clinical experience to date.
2. Over 8,000 migraine attacks have been treated with STS101 so far, with no serious adverse events reported.
3. The Company is continuing to analyze the data from the STS101 ASCEND Phase 3 open-label, long-term safety trial.
Satsuma Pharmaceuticals Inc has been trading between a 52-week high of $7 and a 52-week low of $2.51. The stock has a market cap of $248 Million.
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product candidate for the acute treatment of migraine. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. DHE products have long been recommended as a first-line therapeutic option for the acute treatment of migraine and have significant advantages over other therapeutics for many patients.